ATF5 and glioblastoma: In contrast, Sun [62] reported no effect of CP-DN-ATF5 on CEBPB levels in 3 GBM lines after 24 h of treatment, while Karpel-Massler [59] found that CP-DN-ATF5 significantly depletes ATF5 protein in GBM lines at 48 but not 24 h of exposure, and it does so by decreasing its stability.